0.200
0.00 (0.00%)
| Penutupan Terdahulu | 0.200 |
| Buka | 0.200 |
| Harga / Jualan (P/S) | 0.780 |
| Harga / Buku (P/B) | 7.10 |
| Margin Operasi (TTM) | -4,347.54% |
| EPS Cair (TTM) | -60.50 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -65.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 861.47% |
| Nisbah Semasa (MRQ) | 2.96 |
| Aliran Tunai Operasi (OCF TTM) | -56.40 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -29.27 M |
| Pulangan Atas Aset (ROA TTM) | -28.54% |
| Pulangan Atas Ekuiti (ROE TTM) | -195.46% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Lyra Therapeutics, Inc. | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | -2.0 |
| Purata | -0.83 |
|
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company’s operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 0.69% |
| % Dimiliki oleh Institusi | 40.31% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |